Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109208 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL20601766 | 0.86 | KDM4E (0.38) | ADRA1AHTR2AHTR2CHRH1ADRA1B | |
| Hydrochloric Acid SCHEMBL3353160 | 0.86 | KDM4E (0.38) | ADRA1AHTR2AHTR2CHRH1ADRA1B | |
| SCHEMBL19741741 | 0.83 | HRH1 (0.37) | CHRNB2CHRNA4ADRA1ACXCR4HTR2A | |
| Trifluoroacetic Acid SCHEMBL5767772 | 0.74 | HRH4 (0.38) | — | |
| SCHEMBL712267 | 0.73 | — | — | |
| SCHEMBL4071580 | 0.72 | ADRA1A (0.33) | ADRA1AADRA1D | |
| SCHEMBL238844 | 0.71 | — | — | |
| SCHEMBL4067122 | 0.71 | ADRA1A (0.37) | ADRA1AADRA1DHRH1 | |
| SCHEMBL4073713 | 0.71 | HRH1 (0.38) | ADRA1AHTR2AHTR2CHRH1ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | disclosed |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7579344-B2 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20060229329-A1 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229329-A1 | Pyrimidine derivatives possessing cell-cycle inhibitors activity | TYMP, CCNI, MKI67 | CHRNB2 4859/4885CHRNA4 4834/4885ADRA1A 3312/4885 |
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM3A, KDM1A | CHRNB2 2647/4885CHRNA4 2631/4885ADRA1A 4249/4885 |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | CHRNB2 2650/4885CHRNA4 2470/4885ADRA1A 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.